ALLO Allogene Therapeutics Inc

USD 4.47 0.01 0.224215
Icon

Allogene Therapeutics Inc (ALLO) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 4.47

+0.01 (+0.22)%

USD 0.75B

1.38M

USD 9.80(+119.24%)

USD 16.60 (+271.36%)

Icon

ALLO

Allogene Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 4.47
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.75B

USD 16.60 (+271.36%)

USD 4.47

Allogene Therapeutics Inc (ALLO) Stock Forecast

Show ratings and price targets of :
USD 9.80
(+119.24%)

Based on the Allogene Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Allogene Therapeutics Inc is USD 9.80 over the next 12 months. Allogene Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Allogene Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Allogene Therapeutics Inc’s stock price was USD 4.47. Allogene Therapeutics Inc’s stock price has changed by +2.05% over the past week, -12.70% over the past month and -9.15% over the last year.

No recent analyst target price found for Allogene Therapeutics Inc
No recent average analyst rating found for Allogene Therapeutics Inc

Company Overview Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) ...Read More

https://www.allogene.com

210 East Grand Avenue, South San Francisco, CA, United States, 94080

232

December

USD

USA

Adjusted Closing Price for Allogene Therapeutics Inc (ALLO)

Loading...

Unadjusted Closing Price for Allogene Therapeutics Inc (ALLO)

Loading...

Share Trading Volume for Allogene Therapeutics Inc Shares

Loading...

Compare Performance of Allogene Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALLO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Allogene Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing ALLO

Symbol Name ALLO's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Allogene Therapeutics Inc (ALLO) Stock

Based on ratings from 3 analysts Allogene Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.

Unfortunately we do not have enough data on ALLO's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for ALLO is USD 9.80 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 7.

Unfortunately we do not have enough data on ALLO's stock to indicate if its overvalued.

The last closing price of ALLO's stock was USD 4.47.

The most recent market capitalization for ALLO is USD 0.75B.

Based on targets from 3 analysts, the average taret price for ALLO is projected at USD 9.80 over the next 12 months. This means that ALLO's stock price may go up by +119.24% over the next 12 months.

We can't find any ETFs which contains Allogene Therapeutics Inc's stock.

As per our most recent records Allogene Therapeutics Inc has 232 Employees.

Allogene Therapeutics Inc's registered address is 210 East Grand Avenue, South San Francisco, CA, United States, 94080. You can get more information about it from Allogene Therapeutics Inc's website at https://www.allogene.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...